Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Cormedix
(NASDAQ:CRMD)
Intraday
$5.31
0.12
[2.31%]
After-Hours
$5.31
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$5.31
0.12
[2.31%]
At close: Apr 26
$5.31
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Cormedix Stock (NASDAQ:CRMD)
Cormedix Stock (NASDAQ: CRMD)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, April 19, 2024
CorMedix Inc. Announces CMS Grants Transitional Drug Add-On Payment To DefenCath
Benzinga Newsdesk
-
Apr 19, 2024, 8:31AM
Monday, April 15, 2024
CorMedix Announces U.S. Inpatient Commercial Availability Of DefenCath
Benzinga Newsdesk
-
Apr 15, 2024, 8:40AM
Friday, April 12, 2024
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Apr 12, 2024, 4:31PM
Thursday, April 11, 2024
Two Of CorMedix Abstracts Accepted For Presentation At SHEA Conference
Benzinga Newsdesk
-
Apr 11, 2024, 8:37AM
Tuesday, April 09, 2024
JMP Securities Reiterates Market Outperform on Cormedix, Maintains $19 Price Target
Benzinga Newsdesk
-
Apr 9, 2024, 8:39AM
Needham Reiterates Buy on Cormedix, Maintains $10 Price Target
Benzinga Newsdesk
-
Apr 9, 2024, 6:08AM
Monday, April 08, 2024
CorMedix Inc. Announces 5-Year Contract With Dialysis Provider, ARC Dialysis For The Supply Of DefenCath
Benzinga Newsdesk
-
Apr 8, 2024, 8:41AM
Wednesday, March 13, 2024
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $9
Benzinga Newsdesk
-
Mar 13, 2024, 10:57AM
Tuesday, March 12, 2024
Needham Maintains Buy on Cormedix, Maintains $10 Price Target
Benzinga Newsdesk
-
Mar 12, 2024, 4:35PM
Cormedix Q4 GAAP EPS $(0.26) Misses $(0.20) Estimate; Cash And Short-Term Investments Of $76M
Benzinga Newsdesk
-
Mar 12, 2024, 7:33AM
Earnings Scheduled For March 12, 2024
Benzinga Insights
-
Mar 12, 2024, 5:35AM
Monday, March 11, 2024
Cormedix Earnings Preview
Benzinga Insights
-
Mar 11, 2024, 2:01PM
Wednesday, January 31, 2024
Truist Securities Maintains Buy on Cormedix, Lowers Price Target to $14-Report Released on 30 January 2024
Benzinga Newsdesk
-
Jan 31, 2024, 1:43PM
Monday, January 08, 2024
CorMedix Inc. Announces Commercial And Operational Updates Related To Its Business And Anticipated Launch Of DefenCath
Benzinga Newsdesk
-
Jan 8, 2024, 8:54AM
Monday, December 04, 2023
CorMedix Inc. Announces Partnership With The Leapfrog Group
Benzinga Newsdesk
-
Dec 4, 2023, 8:36AM
Wednesday, November 15, 2023
Why CorMedix Stock Popped Wednesday
Ryan Gustafson
-
Nov 15, 2023, 4:12PM
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Nov 15, 2023, 2:04PM
Needham Maintains Buy on Cormedix, Lowers Price Target to $10
Benzinga Newsdesk
-
Nov 15, 2023, 1:52PM
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $10
Benzinga Newsdesk
-
Nov 15, 2023, 1:47PM
Truist Securities Reiterates Buy on Cormedix, Maintains $18 Price Target
Benzinga Newsdesk
-
Nov 15, 2023, 1:46PM
CorMedix shares are trading higher after the company reported better-than-expected Q3 EPS results. Also, the company received FDA approval for DefenCath under NDA: 214520.
Benzinga Newsdesk
-
Nov 15, 2023, 1:03PM
JMP Securities Reiterates Market Outperform on Cormedix, Maintains $19 Price Target
Benzinga Newsdesk
-
Nov 15, 2023, 12:57PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
-
Nov 15, 2023, 12:31PM
Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
Lisa Levin
-
Nov 15, 2023, 11:08AM
CorMedix Receives FDA Approval For DefenCath Under NDA: 214520
Benzinga Newsdesk
-
Nov 15, 2023, 9:30AM
Why CorMedix Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Nov 15, 2023, 8:07AM
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
-
Nov 15, 2023, 8:06AM
Tuesday, November 14, 2023
Cormedix Q3 EPS $(0.17) Beats $(0.21) Estimate
Benzinga Newsdesk
-
Nov 14, 2023, 4:45PM
CorMedix Q3 2023 $(0.17) Vs $(0.17) YoY
Benzinga Newsdesk
-
Nov 14, 2023, 4:19PM
Earnings Scheduled For November 14, 2023
Benzinga Insights
-
Nov 14, 2023, 8:23AM
Wednesday, October 11, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Oct 11, 2023, 1:35PM
Friday, September 08, 2023
CorMedix Inc. Announces Publication Of Phase 3 LOCK IT-100 Study Data In The Clinical Journal Of The American Society Of Nephrology
Benzinga Newsdesk
-
Sep 8, 2023, 8:35AM
Wednesday, August 30, 2023
CorMedix Inc. Announces Issuance Of U.S. Patent Covering Lead Product Defencath
Happy Mohamed
-
Aug 30, 2023, 8:04AM
Thursday, August 10, 2023
CorMedix's DefenCath Aims to Tackle Catheter-Related Blood Stream Infections: Analyst
Vandana Singh
-
Aug 10, 2023, 12:35PM
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 11:00AM
The Latest Analyst Ratings for Cormedix
Benzinga Insights
-
Aug 10, 2023, 10:01AM
RBC Capital Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $6
Benzinga Newsdesk
-
Aug 10, 2023, 8:38AM
Tuesday, August 08, 2023
Needham Maintains Buy on Cormedix, Lowers Price Target to $12
Benzinga Newsdesk
-
Aug 8, 2023, 1:45PM
Cormedix Q2 EPS $(0.25) Misses $(0.24) Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 7:42AM
Earnings Scheduled For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 4:48AM
Thursday, June 29, 2023
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jun 29, 2023, 1:52PM
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
Jun 29, 2023, 1:37PM
Why Cormedix (CRMD) Stock Is Getting Hammered
Henry Khederian
-
Jun 29, 2023, 9:22AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jun 29, 2023, 9:12AM
Why CorMedix Are Trading Lower By 22%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jun 29, 2023, 8:18AM
Cormedix shares are trading lower after the company priced public offering of 7.5 million shares at $4/share and pre-funded warrants to purchase up to 2.5 million shares at $3.999/pre-funded warrant.
Benzinga Newsdesk
-
Jun 29, 2023, 5:35AM
Cormedix Priced Its Previously Announced Underwritten Public Offering Of 7.5M Shares At $4/Share And Pre-funded Warrants To Purchase Up To An Aggregate Of 2.5M Shares At $3.999/Pre-funded Warrant
Benzinga Newsdesk
-
Jun 29, 2023, 4:30AM
Wednesday, June 28, 2023
CorMedix Inc. Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants; No Size Disclosed
Happy Mohamed
-
Jun 28, 2023, 4:09PM
Wednesday, June 21, 2023
Analyst Ratings for Cormedix
Benzinga Insights
-
Jun 21, 2023, 12:00PM
Needham Reiterates Buy on Cormedix, Maintains $13 Price Target
Benzinga Newsdesk
-
Jun 21, 2023, 11:37AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch